Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising ...

Incorporating mpMRI before TURBT improves bladder cancer-specific survival in patients with suspected MIBC. The BladderPath trial aimed to reduce time to radical treatment by comparing mpMRI before ...

The combination of enfortumab vedotin and pembrolizumab improved event-free survival, overall survival, and pathological complete response in muscle-invasive bladder cancer patients ineligible for ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...

Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...